In our opinion, further studies are needed to better understand the oncogenic role of RARG rearrangements, and the molecular features of both the chimeric transcript and fusion protein, in particular to define the best therapy for these APL atypical patients. This evidence concerns the gene RARG and acute promyelocytic leukemia.